WO2006133866A3 - Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients - Google Patents

Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients Download PDF

Info

Publication number
WO2006133866A3
WO2006133866A3 PCT/EP2006/005575 EP2006005575W WO2006133866A3 WO 2006133866 A3 WO2006133866 A3 WO 2006133866A3 EP 2006005575 W EP2006005575 W EP 2006005575W WO 2006133866 A3 WO2006133866 A3 WO 2006133866A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell proliferative
proliferative disorder
survival
prediction
breast cell
Prior art date
Application number
PCT/EP2006/005575
Other languages
French (fr)
Other versions
WO2006133866A2 (en
Inventor
Dimo Dietrich
Ralf Lesche
Inko Nimmrich
Sabine Maier
Original Assignee
Epigenomics Ag
Dimo Dietrich
Ralf Lesche
Inko Nimmrich
Sabine Maier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenomics Ag, Dimo Dietrich, Ralf Lesche, Inko Nimmrich, Sabine Maier filed Critical Epigenomics Ag
Publication of WO2006133866A2 publication Critical patent/WO2006133866A2/en
Publication of WO2006133866A3 publication Critical patent/WO2006133866A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for prognosis and/or predicted outcome of treatment with estrogen treatment of breast cell proliferative disorder patients, in particular breast carcinoma. This is achieved by determining the expression level of PITX2 or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. The invention also relates to sequences and oligonucleotides which can be used within the described methods.
PCT/EP2006/005575 2005-06-11 2006-06-09 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients WO2006133866A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05012606 2005-06-11
EP05012606.9 2005-06-11

Publications (2)

Publication Number Publication Date
WO2006133866A2 WO2006133866A2 (en) 2006-12-21
WO2006133866A3 true WO2006133866A3 (en) 2007-05-03

Family

ID=37532649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005575 WO2006133866A2 (en) 2005-06-11 2006-06-09 Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients

Country Status (1)

Country Link
WO (1) WO2006133866A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4083232A4 (en) * 2019-12-26 2024-03-20 Anchordx Medical Co., Ltd. Combination of dna methylation biomarkers, and detection method therefor and kit thereof
CN110872631B (en) * 2019-12-26 2021-08-10 广州市基准医疗有限责任公司 DNA methylation biomarker combination, detection method and kit
US11851714B2 (en) 2019-12-26 2023-12-26 Anchordx Medical Co., Ltd. Combinations, detection methods and kits of DNA methylation biomarker

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035803A2 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035803A2 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARBECK NADIA ET AL: "Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424)", CANCER RESEARCH, vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4617 - 4622, XP002419683, ISSN: 0008-5472 *
SZYF MOSHE ET AL: "DNA methylation and breast cancer.", BIOCHEMICAL PHARMACOLOGY 15 SEP 2004, vol. 68, no. 6, 15 September 2004 (2004-09-15), pages 1187 - 1197, XP002419684, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2006133866A2 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
Vriens et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer
WO2008115419A3 (en) Gene expression markers for prediction of patient response to chemotherapy
WO2005121360A3 (en) Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
NZ593224A (en) Gene expression markers (fap) for colorectal cancer prognosis
WO2008079374A3 (en) Methods and compositions for selecting and using single nucleotide polymorphisms
WO2005059172A3 (en) Method and nucleic acids for the improved treatment of breast cell proliferative disorders
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
WO2005100606A3 (en) Gene expression markers for predicting response to chemotherapy
EP1985715A3 (en) ESR1 and cervical cancer
WO2008106453A3 (en) Utility of b-raf dna mutation in diagnosis and treatment of cancer
NZ596545A (en) Improved detection of mage-a expression
WO2008087040A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders
WO2008134596A3 (en) Use of methylated or unmethylated line-i dna as a cancer marker
NZ627864A (en) Cancer patient selection for administration of wnt signaling inhibitors using rnf43 mutation status
WO2007135568A3 (en) A METHOD FOR PREDICTING RESPONSIVENESS TO TNFα BLOCKING AGENTS
WO2009103790A3 (en) Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
NZ628598A (en) Vegf polymorphisms and anti-angiogenesis therapy
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
Villalba et al. Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients
WO2005106041A3 (en) Kits and reagents for use in diagnosis and prognosis of genomic disorders
WO2008063655A3 (en) Dna methylation markers and methods of use
WO2008011620A3 (en) Methods and nucleic acids for analyses of cellular proliferative disorders
Chen et al. An insertion/deletion polymorphism in the 3′ untranslated region of β-transducin repeat-containing protein (βTrCP) is associated with susceptibility for hepatocellular carcinoma in Chinese

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762005

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762005

Country of ref document: EP

Kind code of ref document: A2